Skip to Main Content
Home
Search
Study Topics
Glossary
Full Text View
Tabular View
No Study Results Posted
Related Studies
Recombinant Human Interferon Beta-1a (Avonex) for the Treatment of Patients With HTLV-1-Associated Myelopathy (HAM)
This study has been completed.
Study NCT00001785 Information provided by National Institutes of Health Clinical Center (CC)
First Received: November 3, 1999 Last Updated: March 3, 2008
History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
HTLV-I Infection
Spinal Cord Disease
Tropical Spastic Paraparesis
Additional conditions recognized in this trial
HTLV-I Infections
Infection
Paraparesis
Paraparesis, Spastic
Paraparesis, Tropical Spastic
Spinal Cord Diseases
More general conditions related to this trial
Central Nervous System Diseases
Central Nervous System Infections
Central Nervous System Viral Diseases
Deltaretrovirus Infections
Immune System Diseases
Immunologic Deficiency Syndromes
Myelitis
Nervous System Diseases
Neurologic Manifestations
Paresis
Retroviridae Infections
RNA Virus Infections
Signs and Symptoms
Virus Diseases
Additional drug interventions recognized in this trial
Interferon beta 1a
Interferon Type I, Recombinant
Interferon-beta
Interferons
More general drug interventions related to this trial
Adjuvants, Immunologic
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Anti-Infective Agents
Antineoplastic Agents
Antiviral Agents
Growth Inhibitors
Growth Substances
Immunologic Factors
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses
Sponsors listed in this trial
National Institute of Neurological Disorders and Stroke (NINDS)
Back to top of Main Content
